August 7, 2019
SymBio Pharmaceuticals Limited
Fuminori Yoshida
Representative Director
President and Chief Executive Officer
(Securities Code: 4582)

Revision to Earnings Forecasts for FY 2019 and Mid-Range Plan (FY 2019 to FY 2022)

TOKYO, Japan, August 7, 2019 -- SymBio Pharmaceuticals Limited (Headquarters: Tokyo, "SymBio") today announced that the Company's Board of Directors today approved the following revision to the Earnings Forecasts for the fiscal year ending December 31, 2019 and the Mid-Range Plan for the fiscal years ending December 31, 2019 to 2022, previously announced on February 7, 2019, in accordance with the current performance trend and outlook.

1. Revision to Earnings Forecast

(1) Revision to the earnings forecast for FY 2019 (January 1, 2019 to December 31, 2019)

	Net Sales	Operating Profit (Loss)	Ordinary Profit (Loss)	Net Profit (Loss)	Earnings (Loss) per Share
	Million of Yen	Million of Yen	Million of Yen	Million of Yen	Yen
Previous Forecast (A)	4,465	△3,587	△3,612	△3,616	△175.52
Revised Forecast (B)	3,092	△3,780	△3,856	△3,859	△167.66
Change Amount (B-A)	△1,372	△193	△244	△243	—
Change Percentage (%)	△30.7	—	—	—	—
[Reference] Prior Year Results (FY 2018)	3,835	△2,656	△2,748	△2,752	△165.52

(2) Reason for Revision

The Company currently imports lyophilized powder formulation of TREAKISYM® from Astellas Deutschland GmbH ("Astellas Germany"), a consolidated subsidiary of Astellas Pharma Inc. ("Astellas Pharma") and, after carrying out quality testing and packaging, markets the product in Japan through its business partner, Eisai. During the second quarter of the fiscal year ending December 31, 2019, the inclusion of foreign substance or visual defects were detected in the 100mg presentation of TREAKISYM® imported from Astellas Germany at a rate significantly higher than what is permissible under the quality standards agreed between the Company and Astellas Germany. The Company will return all defective batches to Astellas Germany and has asked Astellas to ensure that all future

shipments are free from such quality issues. At the same time, the Company has urged Astellas Germany to identify the root causes of defects and accelerate the manufacturing and supply of replacement batches.
Under these circumstances, shipments in the second half of 2019 may be below the Company's originally planned shipment volume as supply of replacement batches may be delayed to the first quarter of 2020. Accordingly, the Company has determined to revise the Earnings Forecast for the fiscal year ending December 2019.
The increase in Operating Loss shown above is the result of a reduction in Net Sales, partially mitigated by a 294 million yen reduction in Selling, General and Administrative Expenses (reduced to 4,760 million yen from the originally anticipated 5,053 million yen).

The Company has urged Astellas Germany as the supplier, and Astellas Pharma, to ensure that product supply obligations are met. The Company will advance the discussion to fulfill its responsibility to ensure stable supply of high-quality product, which is an essential part of its mission as a pharmaceutical company.

2. Revision to the Mid-Range Plan

(1) Revision to the planned figures

	Previous Plan for FY 2019	Revised Plan for FY 2019
	Million of Yen	Million of Yen
Net Sales	4,465	3,093
Operating Profit (Loss)	△3,587	△3,780
Ordinary Profit (Loss)	△3,612	△3,857
Net Profit (Loss)	△3,616	△3,859

(2) Reason for Revision

The reason for the revision to the earnings forecast for FY 2019 is stated in 1- (1) above.
The Company is currently assessing the potential impact on fiscal years 2020, 2021 and 2022 in the Mid-Range Plan. Any material impact will be disclosed by the Company in a timely manner.

*Earnings forecasts, financial projections, and other forecasts or forward looking statements contained in this disclosure have been prepared by the Company at its discretion and based on information available to the Company as of the date of this disclosure. Actual results may differ materially from the information contained in this disclosure as a result of changes to assumptions or conditions.

[Contact]
Investor Relations
Tel: +81 (0)3 5472 1125